VIEW MOREPresented at ASCO GU 2025, results of the phase 3 TALAPRO-2 trial support a new standard-of-care for metastatic castration-resistant prostate cancer
VIEW MOREVHIO Joins JANE-2, a Comprehensive EU Initiative to Advance Cancer Care Through Seven New EU Networks
VIEW MOREEl Paseíco de la Mama promotes the INSP3KTION project to understand the biological changes that can lead to the development of breast cancer
Latest News
13 February 2025
Presented at ASCO GU 2025, results of the phase 3 TALAPRO-2 trial support a new standard-of-care for metastatic castration-resistant prostate cancer
Results of the multi-center, international phase 3 TALAPRO-2 trial show that the combination of PARP inhibitor talazoparib plus anti-androgen enzalutamide...
13 February 2025
VHIO Joins JANE-2, a Comprehensive EU Initiative to Advance Cancer Care Through Seven New EU Networks
The second Joint Action of the EU on Networks of Expertise on Cancer (JANE-2) officially launched on January 28-29, 2025,...
12 February 2025
El Paseíco de la Mama promotes the INSP3KTION project to understand the biological changes that can lead to the development of breast cancer
The Paseíco de la Mama solidarity initiative has enabled VHIO’s Breast Cancer Group to carry out numerous research projects over...
11 February 2025
Targeting tumor metabolism as a potential therapeutic strategy in MTAP-deleted cancer
Published in the journal Nature Communications*, results from a first-in-human, phase I clinical trial of an oral, potent and reversible...
PRINCIPAL RESEARCHERS
Events
